Therapists Marcela Ot'alora and Bruce Poulter are trained to conduct MDMA-assisted psychotherapy. In this reenactment, they demonstrate how they help guide and watch over a patient who is revisiting traumatic memories while under the influence of MDMA. (Photo: Multidisciplinary Association for Psychedelic Studies)

MD­MA, now in Phase III, shows promise as a PTSD treat­ment

The first time Lori Tip­ton tried MD­MA, she was skep­ti­cal it would make a dif­fer­ence.

“I re­al­ly was, at the be­gin­ning, very ner­vous,” Tip­ton said.

MD­MA is the main in­gre­di­ent in the club drug known as ec­sta­sy or mol­ly. But Tip­ton wasn’t tak­ing pills sold on the street to get high. She was try­ing to treat her post-trau­mat­ic stress dis­or­der by par­tic­i­pat­ing in a clin­i­cal tri­al.

Af­ter tak­ing a dose of pure MD­MA, Tip­ton lay in a qui­et room with two spe­cial­ly trained psy­chother­a­pists. They sat next to her as she re­called some of her deep­est trau­mas, such as dis­cov­er­ing her moth­er’s body af­ter Tip­ton’s moth­er killed two peo­ple and then her­self in a mur­der-sui­cide.

“In the em­brace of MD­MA,” Tip­ton said, she could re­vis­it that mo­ment with­out the usu­al ter­ror and pan­ic. “I was able to find such em­pa­thy for my­self.”

Sci­en­tists are test­ing how phar­ma­ceu­ti­cal-grade MD­MA can be used in com­bi­na­tion with psy­chother­a­py to help pa­tients with a se­vere form of PTSD that has not re­spond­ed to oth­er treat­ments. Un­like street drugs, which may be adul­ter­at­ed and un­safe, re­searchers use a pure, pre­cise­ly dosed form of the drug.

MD­MA is not yet avail­able as a treat­ment for PTSD out­side of clin­i­cal tri­als. But pro­po­nents are aim­ing for ap­proval by the Food and Drug Ad­min­is­tra­tion, which grant­ed break­through ther­a­py sta­tus to MD­MA-as­sist­ed psy­chother­a­py in 2017.

Re­searchers are con­duct­ing Phase 3 clin­i­cal tri­als at more than a dozen sites. Clin­i­cians who treat PTSD are hope­ful the next round of tri­als will show that MD­MA treat­ment is an ef­fec­tive op­tion to re­lieve pa­tient suf­fer­ing.

“The prob­lem is we haven’t had a new drug to treat PTSD in over 17 years,” said Dr. Sue Sis­ley, a physi­cian and pres­i­dent of the Scotts­dale Re­search In­sti­tute, based in Ari­zona. “There are cer­tain ill­ness­es that are just in­tractable and not re­spon­sive to tra­di­tion­al ther­a­py, and we need to start think­ing more broad­ly.”

But MD­MA is a Sched­ule I con­trolled sub­stance, which means it cur­rent­ly has no ac­cept­ed med­ical use and has a “high po­ten­tial for abuse” (some­thing that MD­MA’s ther­a­peu­tic pro­po­nents dis­pute). Be­cause of that des­ig­na­tion, the cur­rent re­search tri­als are pri­vate­ly fund­ed by the Mul­ti­dis­ci­pli­nary As­so­ci­a­tion for Psy­che­del­ic Stud­ies, or MAPS.

‘Any­where I Would Feel Un­safe’

Tip­ton strug­gled for years with PTSD be­fore she was treat­ed with MD­MA. She said life with PTSD was like “see­ing the world through dirty gog­gles.”

“Any­where I would feel un­safe,” the 40-year-old from New Or­leans said. “I would feel like I had to al­ways be vig­i­lant be­cause if I didn’t, some­thing bad was go­ing to hap­pen.”

Tip­ton de­scribed her 20s as a cat­a­log of tragedy and trau­ma. It be­gan when her broth­er fa­tal­ly over­dosed in her home. Af­ter his death, she be­gan car­ing for her moth­er, who strug­gled with men­tal ill­ness. In 2005, Tip­ton’s moth­er killed two peo­ple and then her­self. Tip­ton dis­cov­ered their bod­ies.

“I com­plete­ly just dis­as­so­ci­at­ed. I couldn’t be­lieve what I was see­ing,” Tip­ton said.

The trau­mas con­tin­ued to pile up. The place she lived was de­stroyed when Hur­ri­cane Ka­t­ri­na hit New Or­leans, and the fol­low­ing year, she was raped.

As the years went by, Tip­ton had pan­ic at­tacks and ter­ri­ble anx­i­ety. She tried every­thing to treat her symp­toms: talk ther­a­py, an­ti­de­pres­sants, hyp­nother­a­py, med­i­ta­tion and yo­ga. Noth­ing worked. She went through life ex­haust­ed and ap­a­thet­ic, con­stant­ly trig­gered and strug­gling to be in­ti­mate with peo­ple close to her.

Then Tip­ton en­rolled in the Phase 2 clin­i­cal tri­als for MD­MA-as­sist­ed psy­chother­a­py.

MD­MA And Ther­a­py To­geth­er

MD­MA was first syn­the­sized in 1912, and its ther­a­peu­tic ben­e­fits were stud­ied in the 1970s. But those ef­forts stalled when the U.S. fed­er­al gov­ern­ment — in light of the grow­ing pop­u­lar­i­ty of ec­sta­sy as a recre­ation­al drug — des­ig­nat­ed it a Sched­ule I drug in 1985.

In re­cent years, re­search has re­sumed, fund­ed by pri­vate spon­sors such as MAPS.

The treat­ment pro­to­col in the cur­rent tri­al calls for a 12-week course of psy­chother­a­py with spe­cial­ly trained ther­a­pists. Dur­ing that time, there are two or three day­long ses­sions, which be­gin with the pa­tient tak­ing a cal­i­brat­ed dose of MD­MA in pill form.

A team of two ther­a­pists, gen­er­al­ly one man and one woman, then guide the pa­tient through the eight-hour MD­MA “ses­sion.” Lat­er, there’s fol­low-up talk ther­a­py, with­out the drug, to help the pa­tient process feel­ings, thoughts or im­pres­sions that came up while un­der the in­flu­ence of the drug.

“MD­MA al­lows you to con­tact feel­ings and sen­sa­tions in a much more di­rect way,” said Saj Razvi, a Col­orado-based psy­chother­a­pist who was a clin­i­cal in­ves­ti­ga­tor in the Phase 2 tri­als.

How MD­MA works in the brain is not com­plete­ly un­der­stood. The psy­choac­tive drug boosts chem­i­cals like sero­tonin and oxy­tocin. It al­so tamps down ac­tiv­i­ty in the amyg­dala, a part of the brain that process­es fear. This may lead to a state char­ac­ter­ized by height­ened feel­ings of safe­ty and so­cial con­nec­tion.

“Trau­ma hap­pens in iso­la­tion,” Razvi said. “One of the things that MD­MA does is, re­al­ly, lets you know that you are not alone.”

PTSD In Re­mis­sion

Af­ter the Phase 2 tri­als of MD­MA-as­sist­ed treat­ments con­clud­ed in 2017, re­searchers found that 54% of the 72 pa­tients who took MD­MA had im­proved to the point that they no longer fit the di­ag­no­sis for PTSD (com­pared with 23% in the con­trol group).

And the ben­e­fi­cial ef­fects of the treat­ment ap­peared to in­crease over time. A year lat­er, the num­ber who no longer had PTSD had risen to 68%.

“That was as­ton­ish­ing,” Sis­ley said. “Even with the best phar­ma­ceu­ti­cal reg­i­men, you rarely ever see pa­tients go in­to re­mis­sion.”

She said she hopes to of­fer her pa­tients MD­MA-as­sist­ed psy­chother­a­py as soon as pos­si­ble, maybe be­fore the drug re­ceives full FDA ap­proval.

Brad Burge, a spokesman for MAPS, said that, be­yond spon­sor­ing the MD­MA tri­al, the or­ga­ni­za­tion is work­ing to get the FDA to in­clude the drug in its ex­pand­ed ac­cess pro­gram, which can al­low in­di­vid­ual pa­tients to be ap­proved to use drugs that are still be­ing stud­ied.

Burge said the goal is to make MD­MA-as­sist­ed psy­chother­a­py avail­able as a pre­scrip­tion treat­ment in a spe­cial­ty clin­ic to any­one with PTSD.

And MAPS is work­ing to per­suade pub­lic and pri­vate in­sur­ance plans to cov­er the treat­ment, Burge said. He es­ti­mates that for pa­tients pay­ing en­tire­ly out-of-pock­et, a 12-week course of treat­ment would cost be­tween $5,000 and $10,000.

Most of the cost is for the guid­ed ther­a­py, not the ac­tu­al drug.

Trans­for­ma­tive Treat­ment

Tip­ton de­scribes her treat­ment with MD­MA as trans­for­ma­tive.

She was able to let go of the trou­bling feel­ings sur­round­ing her moth­er’s death. And, she un­earthed oth­er mem­o­ries, too, feel­ings of joy that had been sealed away.

By her last MD­MA ses­sion, Tip­ton was even able to talk about her sex­u­al as­sault.

A year lat­er, she was re­assessed and no longer qual­i­fied as hav­ing PTSD. Tip­ton said she be­lieves the treat­ment saved her life.

“Every­thing is at my fin­ger­tips for me in a way that it nev­er was be­fore,” she said. “I want that for every­body.”

This sto­ry is part of a part­ner­ship that in­cludes KJZZ, NPR and Kaiser Health News.

Kaiser Health News (KHN) is a na­tion­al health pol­i­cy news ser­vice. It is an ed­i­to­ri­al­ly in­de­pen­dent pro­gram of the Hen­ry J. Kaiser Fam­i­ly Foun­da­tion which is not af­fil­i­at­ed with Kaiser Per­ma­nente.

Click here to see the orig­i­nal sto­ry

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire. Lundbeck

UP­DAT­ED: Deb­o­rah Dun­sire is pay­ing $2B for a chance to leap di­rect­ly in­to a block­buster show­down with a few of the world's biggest phar­ma gi­ants

A year after taking the reins as CEO of Lundbeck, Deborah Dunsire is making a bold bid to beef up the Danish biotech’s portfolio of drugs in what will likely be a direct leap into an intense rivalry with a group of giants now carving up a growing market for new migraine drugs.

Bright and early European time Monday morning the company announced that it will pay up to about $2 billion to buy Alder, a little biotech that is far along the path in developing a quarterly IV formulation of a CGRP drug aimed at cutting back the number of crippling migraines patients experience each month. In a followup call, Dunsire also noted that the company will likely need 200 to 250 reps for this marketing task on both sides of the Atlantic. And analysts were quick to note that the dealmaking at Lundbeck isn’t done, with another $2 billion to $3 billion available for more deals to beef up the pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

San Diego cou­ple charged with steal­ing trade se­crets, open­ing Chi­nese biotech as DOJ crack­down con­tin­ues

A San Diego couple has been charged with stealing trade secrets from a US hospital and opening a business based off those secrets in China as the controversial industry-wide crackdown on alleged corporate espionage continues. On the same day, the Department of Justice announced they had arrested Beijing representative Zhongsan Liu for allegedly trying to obtain research visas for government recruiters.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

One of Biogen’s attempts to branch out has flopped as the biotech scraps a mid-stage program for idiopathic pulmonary fibrosis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Warts for the win: Aclar­is' lead drug clears piv­otal study

Aclaris Therapeutics has found a way to get rid of the warts and all.

The company — which earlier this month decided to focus on its arsenal of kinase inhibitors — on Monday unveiled positive data from a pivotal study testing its lead experimental drug for use in common warts.

The drug, A-101, was tested in a 502-patient study called THWART-2 — patients enrolled had one to six warts before qualifying for the trial. Patients either self-administered A-101 topical solution or a vehicle twice a week over a two-month period. A higher proportion of patients on the drug (a potent hydrogen peroxide topical solution) saw their warts disappear at day 60, versus the vehicle (p<0.0001) — meeting the main goal of the study.  Each secondary endpoint also emerged in favor of A-101, the company said.

Tower Bridge in London [Shutterstock]

#UK­BIO19: Join GSK’s Hal Bar­ron and a group of top biotech ex­ecs for our 2nd an­nu­al biotech sum­mit in Lon­don

Over the past 10 years I’ve made a point of getting to know the Golden Triangle and the special role the UK biopharma industry plays there in drug development. The concentration of world class research institutes, some of the most accomplished scientists I’ve ever seen at work and a rising tide of global investment cash leaves an impression that there’s much, much more to come as biotech hubs are birthed and nurtured.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,700+ biopharma pros reading Endpoints daily — and it's free.

Charles Nichols, LSU School of Medicine

Could psy­che­delics tack­le the obe­si­ty cri­sis? A long­time re­searcher in the field says his lat­est mouse study sug­gests po­ten­tial

Psychedelics have experienced a renaissance in recent years amid a torrent of preclinical and clinical research suggesting it might provide a path to treat mood disorders conventional remedies have only scraped at. Now a preclinical trial from a young biotech suggests at least one psychedelic compound has effects beyond the mind, and — if you believe the still very, very early hype — could provide the first single remedy for some of the main complications of obesity.

Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare neu­ro­mus­cu­lar ail­ment

Acceleron is scrapping a muscular dystrophy development program underway for its number 2 drug in the pipeline after pouring over some failed mid-stage secondary data.

Gone is the ACE-083 project in patients with facioscapulohumeral muscular dystrophy. Their drug hit the primary endpoint on building muscle but flopped on key secondaries for functional improvements in patients, which execs felt was vital to the drug’s success.